Population screening for prostatic carcinoma (CP) is a struggled subject, and we don't know the real utility of it. Nowadays the Authors suggest only survey on little groups. In this study the male population of blood donors of our hospital between 45 and 65 years underwent a complete valutation for CP.
From this study we hope to obtain the following results: a) early diagnosis of CP (eradicable); b) eliminate keeper of neoplastic pathology from blood donations (theoretic risk of transmission of neoplastic cells in immunodepressed patients); c) studying the practicability, if we achieve a high percentage of ahdesions at this program, our model could be exportable.
Anonymous.Review of current data impacting early detection guidelines for prostate cancer. Proceedings of an American Cancer Society workshop. Phoenix, Arizona, March 10–11, 1997.Cancer80: 1808–1881, 1997.
2.
MettlinC., JonesG., AveretteH.Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers (see comments).CA Cancer J Clin1993; 43: 42–46.
3.
von EschenbachA., HoR., MurphyG.P.American Cancer Society guidelines for the early detection of prostate cancer: update, June 10, 1997.Cancer1997; 80: 1805–1807.
4.
Anonymous.Screening for prostate cancer. American College of Physicians (see comments).Ann Intern Med1997; 126: 480–4.
5.
BrawleyO.W.Prostate carcinoma incidence and patient mortality: the effects of screening and early detection.Cancer1997; 80: 1857–63.
6.
CollinsM.M., BarryM.J.Controversies in prostate cancer screening: analogies to the early lung cancer screening debate.J Am Med Assoc1996; 276: 1976–9.
7.
GannP.H.Interpreting recent trends in prostate cancer incidence and mortality (editorial comment).Epidemiology1997; 8: 117–20.
8.
Lancet. The prostate question, unanswered still.Lancet1997; 349: 443.
9.
DemersR.Y.Prostate cancer trends in southeast Michigan 1973–1992.In Vivo1994; 8: 429–31.
10.
StephensonR.A., SmartC.R., MineauG.P.The fall in incidence of prostate carcinoma: on the down side of a prostate specific antigen induced peak in incidence-data from the Utah Cancer Registry (see comments).Cancer1996; 77: 1342–8.
11.
WingoP.A., RiesL.A., RosenbergH.M., MillerD.S., EdwardsB.K.Cancer incidence and mortality, 1973–1995: a report card for the U.S.Cancer.1998; 82: 1197–207.
12.
National Cancer Institute of Canada: Canadian Cancer Statistics 1998.Toronto, Canada, 1998.
13.
MettlinC.J., MurphyG.P.Why is the prostate cancer death rate declining in the United States?Cancer1998, 82: 249.
14.
HornigerW., ReissiglA., RogatschH.Prostate cancer screening in Tyrol, Austria: experience and results.Eur Urol1999; 35: 523.
15.
LabrieF., CandasB., DupontA.Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomised controlled trial.Prostate1999; 38: 83–91.
16.
HoffmanR.M., ClanonD.L., LittenbergB.Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels.J Gen Intern Med2000; 15: 739–48.
17.
CarterH.B., PearsonJ.D., MetterE.J.Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.JAMA1992; 267: 2215–20.
18.
CarterH.B., PearsonJ.D., WaclawiwZ.Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity.Urology1995; 45: 591–6.
19.
BrawerM.K., BeatieJ., WenerM.H.Screening for prostatic carcinoma with prostate specific antigen: results of the second year.J Urol1993; 150: 106–9.
20.
ChanE.C., SulmasyD.P.What should men know about prostate-specific antigen screening before giving informed consent?Am J Med1998; 105: 266–74.
21.
DenisL.J.Prostate cancer screening and prevention: “realities and hope”.Urology1995; 46(3 suppl. A): S56–S61.
22.
GohaganJ.K., LevinD.L., ProrokJ.C.The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.Control Clin Trials2000; 21(6 suppl.): 249S–406S.
23.
PerronL., MooreL., BairatiI.PSA screening and prostate cancer mortality.CMAJ2002; 166: 586–91.
